Earl, H. M., Hiller, L., Vallier, A., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M., Simcock, R., Rea, D., Raj, S., Woodings, P., Harries, M., Howe, D., Raynes, K., Higgins, H. B., Wilcox, M., Plummer, C., Mansi, J., Gounaris, I., Mahler–Araujo, B., Provenzano, E., Chhabra, A., Abraham, J. E., Caldas, C., Hall, P. S., McCabe, C., Hulme, C., Miles, D., Wardley, A. M., Cameron, D. A., Dunn, J. A., & , (2019). 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, 393(10191), 2599–2612. http://access.bl.uk/ark:/81055/vdc_100086506722.0x000048